


Upd-On Treatment with Pipamperon 8-12 (mean 9) mg (bid) after Treatment with Citalopram 10-20 (mean 30) mg (bid) during 20-60 (mean 33) days (PIPCIT ADD-ON) with HDRS-17 Total score = 29 at Baseline in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



PLACEBO ALL* INVEST. COMPOUND* COMPATOR ALL* PIPCIT ADD-ON (n=5)

A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinica
Transl. Psychiatry 2017; 7: e1577; APR 2000)

BEST AVAILABLE COPY

Figure 1

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON AS ADD-ON .
CITALOPRAM vs SNRI (duloxetine) in MAJOR DEPRESSION




Figure 2

**REMISION RATES (HDRS-17 <=7): COMBO PIPAMPERON AS ADD-
ON - CITALOPRAM vs SNRI (venlafaxine) vs SSRI's vs PLACEBO
in MAJOR DEPRESSION**





Figure 3

Foregoing Treatment During 1-5 (mean 4) days with Pipamperon 8-12 (mean 10) mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-50 (mean 26) mg/day (bid) (PIPCIT FG 1-5) in MDD (HDRS-17 at BL = 23) in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, American Journal of Psychiatry, VOLUME 157, APRIL 2000)

Figure 4

**HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON.
CITALOPRAM WITH A FORE-GOING TREATMENT OF 4 DAYS
WITH PIPAMPERON 10mg/day vs SNRI (duloxetine) in MAJOR
DEPRESSION**




Figure 5

**REMISSION RATES (HDRS-17 <=7): COMBO PIPAMPERON-CITALOPRAM
WITH AFORE-GOING TREATMENT OF 4 DAYS WITH PIPAMPERON 10mg/day
vs SNRI (venlafaxine) in MAJOR DEPRESSION**





Figure 6

Foregoing Treatment During 6-8 (mean 7) days with Pipamperon 8-12 (mean 11 mg/day (bid) Followed With the Combination Treatment of Pipamperon and Citalopram 20-40 (mean 30) mg/day (bid) (PIPCIT FG 6-8) in MDD (HDRS-17 at BL = 28 in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



PIPCIT FG 6-8 (n=3)

COMPARATOR ALL*

INVEST. COMPOUND*

PLACEBO ALL*

A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials, JOURNAL OF GENERAL PSYCHIATRY, VOLUME 53, APRIL 2000)

BEST AVAILABLE COPY

Figure 7

HDRS-17 CHANGE FROM BASELINE: COMBO PIPAMPERON-CITALOPRAM WITH A FORE-GOING TREATMENT OF 7 DAYS WITH PIPAMPERON 11mg/day vs SNRI (duloxetine) in MAJOR DEPRESSION





Figure 8

Foregoing & Add-On Treatment with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid) in MDD in Comparison with the Standard Efficacy of Antidepressants in Clinical Trials*

HDRS-17 REDUCTION OVER 8 WEEKS IN MDD



* A. KHAN et al, Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinics Trials, ARCH. OF GENERAL PSYCHIATRY / VOL 57, APR 2000)

Trials, ARCH. OF GENERAL PSYCHIATRY / VOL 57, APR 2000)

BEST AVAILABLE COPY

Figure 9

**HDRS-17 CHANGE FROM BASELINE: Foregoing & Add-On Treatment
with Pipamperon 8-12 mg/day (bid) and Citalopram 20-40 mg/day (bid)
in comparison with the SNRI duloxetine in MAJOR DEPRESSION**




Figure 10

**REMISSION RATES (HDRS-17 <=7): Foregoing & Add-On
Treatment with Pipamperon 8-12 mg/day (bid) and
Citalopram 20-40 mg/day (bid) in comparison with the
SNRI venlafaxine in MAJOR DEPRESSION**




Figure 11

**Y-BOCS TOTAL SCORE: Foregoing & Add-On Treatment with
Pipamperon 8-16 mg/day (bid) and Citalopram 30-80 mg/day (bid)
in comparison with the SSRI fluvoxamine in OCD**




Figure 12

**Y-BOCS OBSESSION SCORE: Foregoing & Add-On Treatment
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day
(bid) in comparison with the SSRI fluvoxamine in OCD**




Figure 13

**Y-BOCS COMPELSION SCORE: Foregoing & Add-On Treatment
with Pipamperon 8-15 mg/day (bid) and Citalopram 30-80 mg/day
(bid) in comparison with the SSRI fluvoxamine in OCD**




Figure 14

**CGI-SEVERITY SCORE: Foregoing & Add-On Treatment with Pipamperon
8 mg/day (bid) and Citalopram 20-40 mg/day (bid) in comparison with the
SSRI in Panic Disorder**




Figure 15